HTLV-I/IIとT細胞の増殖について

Effect of Gemcitabine based chemotherapy on the immunogenicity of pancreatic tumour cells and T-cells.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2020

Gemcitabine alters the proteasome composition and immunopeptidome of tumour cells.

Oncoimmunology·2018

The T4 molecule: function and structure.

Immunology today·2014

Treatment patterns, outcomes, and resource utilization of patients with metastatic melanoma in the U.K.: the MELODY study.

The British journal of dermatology·2013

Supernatants derived from chemotherapy-treated cancer cell lines can modify angiogenesis.

British journal of cancer·2012

Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells.

British journal of cancer·2011

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Lancet (London, England)·2026

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

Lancet (London, England)·2026

Advancing the relevance of clinical trials for older patients.

Lancet (London, England)·2026

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

Lancet (London, England)·2026

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Lancet (London, England)·2026

Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

Lancet (London, England)·2026

Tertiary lymphoid structures as biomarkers and therapeutic targets in neoadjuvant cancer immunotherapy.

Frontiers in immunology·2026

The hidden tumour: giant anterior mediastinal thymolipoma, an incidental finding.

Polish journal of pathology : official journal of the Polish Society of Pathologists·2026

FADS1-mediated Efferocytosis in Tumor-Associated Macrophages Shapes an Immunosuppressive Microenvironment in Gastric Cancer.

Cellular and molecular life sciences : CMLS·2026

The tumoural landscape of lymphocytes and immune pathways in immunotherapy-treated melanoma patients.

Genes and immunity·2026

Strategic engineering B cell immunity for cancer immunotherapy.

Journal of controlled release : official journal of the Controlled Release Society·2026

An Endometrioid Carcinoma With an Adenoma Malignum-like Pattern of Invasion: New Insight into Molecular Features.

International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists·2026

関連する実験動画

HTLV-I/IIとT細胞の増殖について

関連する概念動画

Effect of Gemcitabine based chemotherapy on the immunogenicity of pancreatic tumour cells and T-cells.

Gemcitabine alters the proteasome composition and immunopeptidome of tumour cells.

The T4 molecule: function and structure.

Treatment patterns, outcomes, and resource utilization of patients with metastatic melanoma in the U.K.: the MELODY study.

Supernatants derived from chemotherapy-treated cancer cell lines can modify angiogenesis.

Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells.

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

Advancing the relevance of clinical trials for older patients.

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

Tertiary lymphoid structures as biomarkers and therapeutic targets in neoadjuvant cancer immunotherapy.

The hidden tumour: giant anterior mediastinal thymolipoma, an incidental finding.

FADS1-mediated Efferocytosis in Tumor-Associated Macrophages Shapes an Immunosuppressive Microenvironment in Gastric Cancer.

The tumoural landscape of lymphocytes and immune pathways in immunotherapy-treated melanoma patients.

Strategic engineering B cell immunity for cancer immunotherapy.

An Endometrioid Carcinoma With an Adenoma Malignum-like Pattern of Invasion: New Insight into Molecular Features.

関連する実験動画

HTLV-I/IIとT細胞の増殖について

関連する概念動画

関連記事